Vaxcyte announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering. BTIG and Needham & Company are acting as lead managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCVX:
- Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
- Vaxcyte completes enrollment of Phase 1/2 study of VAX-31
- Vaxcyte appoints Whitney Jones as Chief People Officer
- Vaxcyte Appoints Whitney Jones as Chief People Officer
- Needham ups Phathom target, adds to Conviction List as top 2024 pick